Exothera Nucleic Acids will be the World’s First CDMO with Access to Quantoom’s Revolutionary Nfinity™ Platform for the continuous production of RNA which Exothera will offer as a service.

Exothera Nucleic Acids will be the World’s First CDMO with Access to Quantoom’s Revolutionary Nfinity™ Platform for the continuous production of RNA which Exothera will offer as a service.

April 19, 2023PR-M04-23-01

Brussels, Belgium, April 19, 2023  Exothera has partnered with Quantoom Biosciences (“Quantoom”) to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in terms of efficiency, productivity, quality control, cost-effectiveness, and scalability.

Exothera will provide the service through a new business unit, Exothera Nucleic Acids, that focuses on accelerating the process development and manufacturing of RNA vaccines and therapeutics.



Laboratory technician operating the Nfinity™ platform from Quantoom Biosciences


Combining Exothera’s development and manufacturing expertise with Quantoom’s continuous biomanufacturing platform will allow biotech and pharma companies to simplify RNA vaccine development and accelerate their clinical and commercial timelines. By leveraging the Nfinity technology, Exothera will offer development services, non GMP and GMP manufacturing as well as analytical services to pharma/biotech for mRNA and saRNA therapeutic development.

Thibault Jonckheere, CEO of Exothera, commented, "The market potential for RNA therapies continues to grow and expand into new therapeutic areas, but the process of developing a new RNA vaccine or therapeutic is hindered by outdated technology that was never intended to scale for commercialization. We are thrilled to not only announce the launch of our new business unit focused on nucleic acids, but also our strategic collaboration with Quantoom Biosciences. This collaboration enables Exothera to make the highest quality RNA for vaccines and therapeutics with low-risk process development and almost guaranteed product quality from sequence up to mass production in a much shorter time than previously possible.”

"We're thrilled by this new partnership which marks a new milestone for Quantoom, added José Castillo, CEO of Quantoom. “The advantages of continuous manufacturing for RNA are clear, and we believe this partnership will provide significant benefits to biotech and pharma companies developing RNA vaccines and therapeutics. By combining Exothera's expertise with our cutting-edge platform, we can simplify the process and accelerate timelines for RNA development and production. We're excited to see the impact this partnership will have on the industry and ultimately, on patients' lives."

Exothera’s services will be available to biotech and pharmaceutical companies of all sizes and stages of development whether they are starting from a known protein sequence (antigen) or have a product in pre-clinical development or clinical trials. The company is currently accepting inquiries for its services and is actively seeking partnerships with biotech and pharmaceutical companies to support their drug development programs.

Exothera is a contract development, and manufacturing organization (CDMO) dedicated to viral vector and nucleic acids production. As a Univercells company, we benefit from access to novel manufacturing technologies and best-in-class bioprocessing expertise. We are the first CDMO to have access to new, continuous RNA manufacturing technology that enables us to rapidly produce the highest quality RNA for vaccines and therapeutics. We provide accelerated discovery services and process development for non-GMP and GMP production at clinical or commercial scale, faster and more reliably than previously possible. At Exothera and Univercells, our mission is to make life-changing therapies available to all.



Quantoom Biosciences is reinventing mRNA production by developing an RNA Platform (NfinityTM) that encompasses DNA (NplifyTM) and RNA (NtensifyTM) manufacturing and formulation (NcapsulateTM), along with critical reagent supply, from sequence to large scale production. We are a team of scientists, engineers and clinicians committed to solving some of the biggest DNA and RNA production challenges facing vaccines and therapeutics, by delivering greater access and autonomy to mRNA technology. Our facilities are strategically located in Belgium and France, in the heart of Europe, benefiting from an exceptional biotech ecosystem. We are part of Univercells, a global life sciences group that makes biologics available to all.


For more information please contact:


Darren Leva




José Castillo, CEO


chat button